Pharmacology and Biological Efficacy of a Recombinant, Humanized, Single-Chain Antibody C5 Complement Inhibitor in Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardiopulmonary Bypass
Authors:
- Jane C. K. FitchJFJane C. K. Fitch
- Scott RollinsSRScott Rollins
- Louis MatisLMLouis Matis
- Bernadette AlfordBABernadette Alford
- Sary ArankiSASary Aranki
- Charles D. CollardCCCharles D. Collard
- Michael DewarMDMichael Dewar
- John ElefteriadesJEJohn Elefteriades
- Roberta HinesRHRoberta Hines
- Gary KopfGKGary Kopf
- Philip KrakerPKPhilip Kraker
- Lan LiLLLan Li
- 21 December 1999
- journal article
- other
- Published by Wolters Kluwer Health in Circulation
- Vol. 100 (25) , 2499-2506
Abstract
Background —Cardiopulmonary bypass (CPB) induces a systemic inflammatory response that causes substantial clinical morbidity. Activation of complement during CPB contributes significantly to this inflammatory process. We examined the capability of a novel therapeutic complement inhibitor to prevent pathological complement activation and tissue injury in patients undergoing CPB. Methods and Results —A humanized, recombinant, single-chain antibody specific for human C5, h5G1.1-scFv, was intravenously administered in 1 of 4 doses ranging from 0.2 to 2.0 mg/kg before CPB. h5G1.1-scFv was found to be safe and well tolerated. Pharmacokinetic analysis revealed a sustained half-life from 7.0 to 14.5 hours. Pharmacodynamic analysis demonstrated significant dose-dependent inhibition of complement hemolytic activity for up to 14 hours at 2 mg/kg. The generation of proinflammatory complement byproducts (sC5b-9) was effectively inhibited in a dose-dependent fashion. Leukocyte activation, as measured by surface expression of CD11b, was reduced ( P P =0.05) in patients who received 2 mg/kg. Sequential Mini-Mental State Examinations (MMSE) demonstrated an 80% reduction in new cognitive deficits ( P P Conclusions —A single-chain antibody specific for human C5 is a safe and effective inhibitor of pathological complement activation in patients undergoing CPB. In addition to significantly reducing sC5b-9 formation and leukocyte CD11b expression, C5 inhibition significantly attenuates postoperative myocardial injury, cognitive deficits, and blood loss. These data suggest that C5 inhibition may represent a novel therapeutic strategy for preventing complement-mediated inflammation and tissue injury.Keywords
This publication has 42 references indexed in Scilit:
- Cognitive Outcome After Coronary Artery Bypass: A One-Year Prospective StudyThe Annals of Thoracic Surgery, 1997
- Inhibition of complement activity by humanized anti-C5 antibody and single-chain FvMolecular Immunology, 1996
- Current incidence and determinants of perioperative myocardial infarction in coronary artery surgeryAmerican Heart Journal, 1996
- Selection and clinical significance of neuropsychologic testsThe Annals of Thoracic Surgery, 1995
- Microemboli during coronary artery bypass grafting: Genesis and effect on outcomeThe Journal of Thoracic and Cardiovascular Surgery, 1995
- Neutrophil adhesion molecule expression during cardiopulmonary bypass with bubble and membrane oxygenatorsThe Annals of Thoracic Surgery, 1993
- Tumor necrosis factor/cachectin. Induction of hemorrhagic necrosis in normal tissue requires the fifth component of complement (C5).Journal of Experimental Medicine, 1988
- Effects of coronary artery revascularization and perioperative myocardial infarction on left ventricular wall motionInternational Journal of Cardiology, 1987
- Changes in Left Ventricular Performance Related to Perioperative Myocardial Infarction in Coronary Artery Bypass Graft SurgeryThe Annals of Thoracic Surgery, 1983
- Complement Activation during Cardiopulmonary BypassNew England Journal of Medicine, 1981